Ratul Chatterjee, MD
Internal Medicine · Huntington Beach, CANPI 1770597387
Payments from drug & device makers
Across 297 payments — averaging $52.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- AstraZeneca$2K
- Johnson & Johnson$1K
- Amgen$1K
- Lilly USA, LLC$1K
- Pfizer$600
- plus $5K from 27 others
What the payments were for
- Speaking & faculty fees$3,70024%
- Travel & lodging$100%
- Food & beverage$11,71676%
- Education$881%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 45 | $4,696 |
| AstraZeneca | 28 | $1,903 |
| Johnson & Johnson | 24 | $1,290 |
| Amgen(2 entities) | 22 | $1,071 |
| Lilly USA, LLC | 39 | $1,017 |
| Pfizer | 15 | $600 |
| Merck | 8 | $472 |
| GSK | 12 | $452 |
| Novartis | 21 | $449 |
| Aimmune Therapeutics, Inc. | 3 | $374 |
| Bayer | 7 | $343 |
| Amarin Pharma, Inc. | 9 | $327 |
| Novo Nordisk | 13 | $323 |
| Biohaven Pharmaceuticals, Inc. | 5 | $278 |
| Radius Health, Inc. | 10 | $277 |
| Vifor Pharma, Inc. | 2 | $242 |
| E.r. Squibb & Sons, L.L.C. | 3 | $151 |
| Sanofi-aventis U.S. LLC | 3 | $150 |
| Boehringer Ingelheim | 2 | $135 |
| Sanofi Pasteur Inc. | 1 | $127 |
| Nestle Healthcare Nutrition Inc. | 1 | $125 |
| Phathom Pharmaceuticals, Inc. | 1 | $124 |
| Acadia Pharmaceuticals Inc | 1 | $120 |
| Lundbeck LLC | 5 | $115 |
| Eisai Inc. | 3 | $70 |
| Astellas Pharma US Inc | 3 | $66 |
| Regeneron Healthcare Solutions, Inc. | 2 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $46 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Circassia Inc. | 1 | $17 |
| Exact Sciences | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$3,959
- XARELTO$839
- FARXIGA$596
- EVENITY$488
- BREZTRI$466
- ELIQUIS$461
- ZENPEP$374
- MOUNJARO$363
- AIRSUPRA$363
- VERQUVO$336
- UBRELVY$246
- Vascepa$246
- NURTEC ODT$244
- Veltassa$242
- Kerendia$238
- FLUBLOK QUADRIVALENT$127
- FLUZONE HIGH-DOSE$127
- NO PRODUCT DISCUSSED$127
- VOWST$125
- PRALUENT$125
How this compares
$15,514 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 193 | $208,084 |
| FarxigaDapagliflozin Propanediol | 187 | $190,363 |
| OzempicSemaglutide | 144 | $187,563 |
| MounjaroTirzepatide | 81 | $88,444 |
| XareltoRivaroxaban | 55 | $60,285 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $58,095 |
| CreonLipase/Protease/Amylase | 14 | $52,134 |
| JardianceEmpagliflozin | 31 | $40,296 |
| MyrbetriqMirabegron | 40 | $32,696 |
| GemtesaVibegron | 52 | $31,237 |
| TymlosAbaloparatide | 12 | $30,547 |
| ProliaDenosumab | 16 | $28,030 |
| Repatha SureclickEvolocumab | 34 | $20,000 |
| EntrestoSacubitril/Valsartan | 19 | $15,448 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $13,759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $600 | $208,084193 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere | $1,903 | $207,279215 claims |
| Novo NordiskOzempic | $323 | $187,563144 claims |
| Lilly USA, LLCMounjaro | $1,017 | $88,44481 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $452 | $71,85590 claims |
| Johnson & JohnsonXarelto | $1,290 | $60,28555 claims |
| AbbVieCreon | $4,696 | $52,13414 claims |
| Boehringer IngelheimJardiance | $135 | $40,29631 claims |
| Astellas Pharma US IncMyrbetriq | $66 | $32,69640 claims |
| Radius Health, Inc.Tymlos | $277 | $30,54712 claims |
| AmgenProlia | $1,071 | $28,03016 claims |
| NovartisEntresto | $449 | $15,44819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Huntington Beach
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.